{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"MediciNova, Inc."},"Symbol":{"label":"Symbol","value":"MNOV"},"Address":{"label":"Address","value":"4275 EXECUTIVE SQUARE,SUITE 300, LA JOLLA, California, 92037, United States"},"Phone":{"label":"Phone","value":"+1 858 373-1500"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases. It has the acquisition and development of the small molecule therapeutics segments."},"CompanyUrl":{"label":"Company Url","value":"https://www.medicinova.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Kazuko Matsuda","title":"Director & Chief Medical Officer"},{"name":"Yuichi Iwaki","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}